Study
| A Phase II , Randomized, Open-label , multicenter trial |
| Resectable, stage IIIA or IIIB NSCLC |
| Arm A: Nivolumab + Carboplatin + PaclitaxelS->Nivolumab (n=57) |
| Arm B: Carboplatin + Paclitaxel S->PBO (n=29) |
Efficacy
| 24 mos PFS: 67.2% vs 40.9% |
| 24 mos OS: 85.0% vs. 63.6% |
| mPR: 53.0% vs 14.0% |
| PcR: 37.0% vs. 7.0% |
Safety
| Grade3: febrile neutropenia (7% vs.0%), fatigue (4% vs.3%), diarrhea (4% vs.0) |
N Engl J Med 2023; 389:504-513
Perioperative Nivolumab and Chemotherapy in Stage III Non–Small-Cell Lung Cancer
http://doi.org/10.1056/NEJMoa2215530
Reviewed by Elvin Chalabiyev, MD on Aug 20, 2023
